Free Trial
NASDAQ:ENVB

Enveric Biosciences 8/14/2023 Earnings Report

Enveric Biosciences logo
$1.29 +0.01 (+0.78%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$1.30 +0.01 (+0.85%)
As of 05/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enveric Biosciences EPS Results

Actual EPS
-$45.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enveric Biosciences Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Enveric Biosciences' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Enveric Biosciences Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Enveric Biosciences CEO Issues Letter to Shareholders
This Biotech Soared On Key Announcement
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

View Enveric Biosciences Profile

More Earnings Resources from MarketBeat